Scholarlink

Background <p>The monarchE trial enrolled patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC). Although both macrometastasis and micrometastasis were eligible, the number of patients with only micrometastasis was not reported, leaving their prognosis uncertain. This study compared outcomes of patients with 1–3 positive axillary lymph nodes (pALNs), including those with only micrometastases and those with macrometastases, according to monarchE high-risk criteria.</p> Methods <p>We retrospectively reviewed 844 patients with HR-positive/HER2-negative/node-positive EBC from a prospectively maintained institutional database and classified them into four groups: Group 1, 1–3 pALNs (including macrometastasis) with grade 3 tumors or tumors ≥ 5&#xa0;cm; Group 2, 1–3 pALNs (only micrometastasis) with grade 3 tumors or tumors ≥ 5&#xa0;cm; Group 3, 1–3 pALNs (including macrometastasis) with grade &lt; 3 tumors and tumors &lt; 5&#xa0;cm; and Group 4, 1–3 pALNs (only micrometastasis) with grade &lt; 3 tumors and tumors &lt; 5&#xa0;cm. Invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) were analyzed using the Kaplan–Meier method and log-rank test. Univariable Cox models assessed associations between clinical factors and outcomes.</p> Results <p>Group 2 showed outcomes comparable to Group 1 (5-year IDFS: 80.7% vs. 83.7%; DRFS: 89.5% vs. 87.9%). In univariate analysis, only tumor size—rather than Group 2 or histological grade—was prognostic for IDFS and DRFS. Sensitivity analyses restricted to patients undergoing axillary lymph node dissection yielded consistent results.</p> Conclusions <p>Among HR-positive/HER2-negative EBC, high-risk patients with only micrometastasis demonstrated prognoses similar to those with macrometastasis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1–3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月23日

查看全文
  • Takeshi Murata,
  • Masayuki Yoshida,
  • Chikashi Watase,
  • Hinako Maeda,
  • Ayako Nakashoji,
  • Ayumi Ogawa,
  • Natsuko Ohgi,
  • Mengge Chen,
  • Sayako Tsubota,
  • Akiko Maeshima,
  • Eriko Iwamoto,
  • Shin Takayama

摘要

Background

The monarchE trial enrolled patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC). Although both macrometastasis and micrometastasis were eligible, the number of patients with only micrometastasis was not reported, leaving their prognosis uncertain. This study compared outcomes of patients with 1–3 positive axillary lymph nodes (pALNs), including those with only micrometastases and those with macrometastases, according to monarchE high-risk criteria.

Methods

We retrospectively reviewed 844 patients with HR-positive/HER2-negative/node-positive EBC from a prospectively maintained institutional database and classified them into four groups: Group 1, 1–3 pALNs (including macrometastasis) with grade 3 tumors or tumors ≥ 5 cm; Group 2, 1–3 pALNs (only micrometastasis) with grade 3 tumors or tumors ≥ 5 cm; Group 3, 1–3 pALNs (including macrometastasis) with grade < 3 tumors and tumors < 5 cm; and Group 4, 1–3 pALNs (only micrometastasis) with grade < 3 tumors and tumors < 5 cm. Invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) were analyzed using the Kaplan–Meier method and log-rank test. Univariable Cox models assessed associations between clinical factors and outcomes.

Results

Group 2 showed outcomes comparable to Group 1 (5-year IDFS: 80.7% vs. 83.7%; DRFS: 89.5% vs. 87.9%). In univariate analysis, only tumor size—rather than Group 2 or histological grade—was prognostic for IDFS and DRFS. Sensitivity analyses restricted to patients undergoing axillary lymph node dissection yielded consistent results.

Conclusions

Among HR-positive/HER2-negative EBC, high-risk patients with only micrometastasis demonstrated prognoses similar to those with macrometastasis.